
Opinion|Videos|October 18, 2024
Improving Access to Lupus Nephritis Treatment: Strategies and Resources
Key Takeaways
- Financial constraints and limited healthcare access are significant barriers to timely lupus nephritis treatment, affecting patient outcomes.
- Patient assistance programs, educational initiatives, and support groups are crucial resources for facilitating access to lupus nephritis care.
Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support timely access, including how payers are facilitating care.
Advertisement
Episodes in this series

- What challenges or barriers do patients face when accessing lupus nephritis (LN) treatment, and what resources are available to support timely access to treatment?
- How are payers supporting timely access to care in LN?
Advertisement
Related to this article

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5


